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Background: Sri Lanka is a developing country with a high rate of cardiovascular mortality. It is still largely
dependent on thrombolysis for primary management of acute myocardial infarction. The aim of this study was to
present current data on the presentation, management, and outcomes of acute ST-segment-elevation myocardial
infarction (STEMI) at a tertiary-care hospital in Sri Lanka.
Methods: Eighty-one patients with acute STEMI presenting to a teaching hospital in Peradeniya, Sri Lanka, were
included in this observational study.
Results: Median interval between symptom onset and hospital presentation was 60 min (mean 212 min).
Thrombolysis was performed in 73% of patients. The most common single reason for not performing thrombolysis
was delayed presentation. Median door-to-needle time was 64 min (mean, 98 min). Only 16.9% of patients received
thrombolysis within 30 min, and none underwent primary PCI. Over 98% of patients received aspirin, clopidogrel,
and a statin on admission. Intravenous and oral beta blockers were rarely used. Follow-up data were available for
93.8% of patients at 1 year. One-year mortality rate was 12.3%. Coronary intervention was performed in only 7.3%
of patients post infarction.
Conclusion: Late presentation to hospital remains a critical factor in thrombolysis of STEMI patients in Sri Lanka.
Thrombolysis was not performed within 30 min of admission in the majority of patients. First-contact physicians
should receive further training on effective thrombolysis, and there is an urgent need to explore the ways in which
PCI and post-infarction interventions can be incorporated into treatment protocols.
Keywords: ST-segment-elevation myocardial infarction, STEMI, Thrombolysis, Door-to-needle time, Survival, 1-year
mortality, Sri LankaBackground
Sri Lanka is a developing country with a population
of 21 million and a rapidly increasing burden of non-
communicable diseases.
In 2005, the prevalences of hypertension, diabetes, and
dysglycemia were 20%, 11%, and 20%, respectively [1].
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unless otherwise stated.be one of the highest worldwide [2]. Ischemic heart dis-
ease (IHD) is the leading cause of death in Sri Lanka and
accounts for 27.6 deaths per 100,000 people. Data from
2004 to 2012 show a steady increase in hospital mortality
from IHD; in 2012 it accounted for 14.4% all hospital
deaths [3]. This high mortality remains unexplained but
may be attributable in part to the clustering of modifiable
and non-modifiable cardiovascular risk factors.
Acute coronary syndrome (ACS) encompasses a
spectrum of coronary artery diseases, including unstablel. This is an Open Access article distributed under the terms of the Creative
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(STEMI), and non-STEMI.
There has recently been a worldwide transition in the
acute management of ACS. Primary percutaneous coron-
ary intervention (PCI) is steadily being introduced in most
parts of the developed world and middle-income coun-
tries. However, in Sri Lanka, ACS is still managed primar-
ily medically and, in most instances, in non-specialized
general medical units. Rates of secondary prevention of
cardiovascular disease are low in middle-income countries
like Sri Lanka, but offer substantial oppurtunties for fur-
ther development [4].
Clinical trials have provided clinicians with many
evidence-based interventions and medications. These are
augmented by observational studies, which provide useful
information about patients hospitalized for acute coronary
events [5]. Observational studies have revealed differences
and shortcomings in management practices among coun-
tries as well as within different regions of the same country
[6,7]. The development of patient registries is an important
step toward increased awareness of cardiovascular disease
and establishment of appropriate management strat-
egies. Although developed countries already have such
registries, these need to be established in developing
countries so that current preventive and management
strategies can be audited.
At present, there is little information on the management
and outcomes of acute myocardial infarction (AMI) [8] in
Sri Lanka. The aim of this study was to examine current
data on the presentation, management, and outcomes of
acute STEMI at a tertiary-care hospital in Sri Lanka.
Methods
This prospective observational study was carried out at
the Professorial Medical Unit of Peradeniya Teaching
Hospital, Sri Lanka, over a 6-month period beginning
November 2011. This is a busy state-run tertiary-care in-
stitution with a nonselective intake of acute patients.
To be eligible for enrollment, patients had to present
within 24 h of onset of symptoms likely to be of myocardial
origin. In addition, they had to have electrocardiographic
(ECG) changes fulfilling current ECG criteria in the diag-
nosis of acute STEMI or new-onset left bundle-branch
block, and an increase in a biochemical marker of myocar-
dial necrosis where results were available. All patients
presenting with chest pain within the preceding 24 h who
fulfilled ECG criteria for acute STEMI were included in
the study. A diagnosis of STEMI was made by a senior
house officer or registrar on admission and later confirmed
by a consultant physician. Troponin level is not checked at
most government hospitals; when required, the test is per-
formed in a private laboratory at the patient’s expense.
Cardiac troponin levels were therefore not routinely
available to us and were requested only in instanceswhere diagnosis was uncertain. Assessment with history,
physical examination, and ECG was performed for every
patient presenting with chest pain, and those patients
fulfilling the criteria for STEMI were included in the
present study. Patients provided written informed con-
sent prior to collection of management data, which were
extracted from interviews conducted by the authors and
from hospital records.
Following hospital discharge, patients were allowed to
be followed up at their usual clinics. One year from the
onset of STEMI, patients were invited for another inter-
view with the authors. At this visit, patients’ current
symptoms and examination findings were recorded and
data from clinic records regarding management during
the previous year was obtained. An echocardiogram was
performed to assess left ventricular function and to de-
tect new onset of regional wall-motion abnormalities
and other structural abnormalities.
The study did not alter the standard care given to the pa-
tients. Ethical clearance for this study was obtained from
the ethics review committee of the faculty of medicine at
University of Peradeniya, Sri Lanka (2011/EC/22).
Binary logistic regression was used to assess the asso-
ciation of mortality at 1 year with history of smoking,
hypertension, dyslipidemia, time taken for presentation,
door-to-needle time, ejection fraction, and hypotension
during the index admission and the mode (direct vs. redir-
ected) of admission to the hospital. A P value less than
0.05 was considered to be statistically significant.
Results
There were 81 admissions with confirmed STEMI dur-
ing the study period. There were 21 (26%) females and
60 (74%) males and the mean age was 61.7 (SD 10.7)
years. The majority of patients (59.5%) belonged to the
age group of 50–69 years, and a further 20% were from
the 70–79 year group.
Seventeen (21%) were current smokers, 47 (58%) had
smoked at some time during their lives and 34 (42%) pa-
tients had never smoked. None of the females had ever
smoked. Seven patients (8.6%) had previous history of
ischaemic heart disease. Twenty two (27%) had a history
of hypertension, 25 (30.8%) diabetes mellitus and 6 (7%)
isolated dyslipidaemia. Socio-demographic profile, co-
morbidities and risk factors are gven in Table 1.
There were 45 (58%) direct admissions to Teaching
Hospital Peradeniya (THP), 23 (27%) were referred from
the regional hospitals and 11 (12.5%) referred by the
general practitioner (GP).
Time to presentation by direct or redirected admission
is presented in Table 2. Of the patients presenting directly
to our facility, median time from symptom onset to ad-
mission was 60 min, the mean was 212 min. Patients who
had been seen at a peripheral hospital or by a general





Age Mean (years) SD (years)
Males 59.38 10.62
Females 70.70 8.67











Diabetes mellitus 25 30.8
Dyslipidemia 6 7
Ischemic Heart Disease 7 8.6




BMI, body mass index.
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mean, 281 min). The difference did not reach statistical
significance (P = 0.45).
Seventy seven patients (95%) presented with chest pain
and four patients had symptoms other than chest pain.
Forty three patients (53%) had anterior STEMI or new-
onset left bundle-branch block, 32 (40%) had inferior
STEMI, and six (7%) had lateral STEMI. Of the 81 patients
studied, 10 (12.3%) were not eligible for thrombolysis
because of late presentation; thus, 71 patients (87%) were
eligible for thrombolytic therapy, and 59 (72.8%) under-
went thrombolysis with streptokinase.
Twelve patients were therefore eligible on the basis of
arrival time, but three of these (3.7%) had absolute or rela-
tive contraindications to thrombolysis and nine (11.1%)Table 2 Comparison of time to presentation between
direct and redirected admission
Time taken for admission to
tertiary care center (minutes)
Median Mean
Direct admission (n = 45) 60 212
Re-directed admissions (n = 36) 75 281
P = 0.45.eligible patients did not undergo thrombolysis for un-
known reasons. The 12 patients who were eligible for, but
did not undergo, thrombolysis and those who presented
late were treated with either low-molecular-weight hep-
arin or unfractionated heparin.
Median door-to-needle time was 64 min (mean, 98 min).
Ten patients (16.9%) underwent thrombolysis within
30 min, 28 (47.4%) within 60 min and 39 (66%) within
90 min. Twenty (33.9%) underwent thrombolysis more
than 90 min after arriving at the hospital. Time to
thrombolytic therapy is shown in Table 3.
Of the 81 patients presenting to our facility, 99% received
aspirin, 97% received clopidogrel, and 95% received a statin
on admission. Oxygen was given to 79%, analgesics to 61%,
and oral beta blockers to 35%. Only 16% of patients pre-
senting to either a peripheral hospital or a general practi-
tioner received aspirin.
During hospitalization, patients were administered
aspirin (91%), clopidogrel (95%), statin (91%), angiotensin-
converting-enzyme inhibitor (ACEI) or angiotensin-receptor
blocker (ARB) (95%), and nitrates (60%). At discharge, over
88% received a combination of aspirin, clopidogrel, sta-
tin, and ACEI or ARB. At discharge, only 59% of pa-
tients were prescribed nitrates and only 34% were
prescribed beta blockers.
Following thrombolysis, four patients (5%) were man-
aged in the intensive care unit, 38 (47%) in the high-
dependency unit, and remainder in the general medical
unit. One patient developed gastrointestinal bleeding fol-
lowing thrombolysis.
Mean duration of hospital stay following acute STEMI
was 5.5 days. There was no difference in duration of stay
between patients who experienced anterior STEMI and
those who experienced STEMI located elsewhere. Dur-
ing hospitalization, one patient developed bleeding while
on low-molecular-weight heparin, four had reversible ar-
rhythmias, seven developed heart failure, four had heart
failure with reversible cardiogenic shock, and two devel-
oped pneumonia.
A pre-discharge echocardiogram was performed in 72
patients (88%), of whom 10 (12.3%) had an ejection frac-
tion < 40%. Mean ejection fraction of the study population
during the index admission was 48.4% (range, 20–68%).
Follow-up data were available for 93.8% of patients. At
the end of 1 year, 66 (81.5%) of the 81 patients withTable 3 Door-to-needle times of patients receiving
streptokinase
Number Cumulative percentage (%)
≤30 minutes 10 16.9
>30 ≤ 60 minutes 18 47.4
>60 ≤ 90 minutes 11 66
>90 minutes 20 100
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and 10 (12.3%) had died. Thirty-seven patients (45.6%)
had been referred to a specialized cardiology unit, 22
(27%) underwent exercise ECG testing, 10 (12.3%) under-
went coronary angiography, five (6%) underwent percu-
taneous transluminal coronary angiography, and two
(2.3%) underwent coronary artery bypass grafting. Six
patients had been readmitted for cardiac-related prob-
lems, four for heart failure associated with ACS, and
two for ACS. Outcomes of patients at 1-year is tabulated
in Table 4.
At the end of 1 year, six patients (7%) were still smok-
ing; mean systolic and diastolic blood pressures were
128 mmHg and 79 mmHg, respectively; and medications
being used were aspirin (83%), clopidogrel (82%), statin
(90%), and ACEI or ARB (85%).
Echocardiography at 1-year follow-up revealed new-
onset regional wall-motion abnormalities in six patients
(9%), of whom five demonstrated new-onset left ventricu-
lar dysfunction (ejection fraction <40%). Mean ejection
fraction at 1 year was 49%.
Of the ten patients who died, four had anterior STEMI
and six had inferior myocardial infarction during the
index admission. The immediate cause of death is not
known. Thrombolysis was not received by one patient.
There was no significant difference in mean door-to-
needle time between patients who died within the first
year (129 min) and those who were alive at 1-year follow-
up (92 min) (P = 0.3). Mean time to hospital presentation
was 61.8 min in those who died and 247 min in those who
survived. Mean ejection fraction at the index admission
did not differ significantly between non-surviving patients
(49%) and surviving patients (49%). Only one patient had
post-infarction heart failure during the index admission.
Two patients were referred to a cardiologist. The deceased
patients had received aspirin, clopidogrel, and a statin at
admission and at discharge. The presence of diabetes mel-
litus (P = 0.01) and previous IHD (P = 0.05) were associ-
ated with death at 1 year.Table 4 One-year outcomes
Number Percentage (%)
1 year follow up 66 81.5
Lost to follow up 5 6
Deceased at 1 year 10 12.3
Referral done to specialized
cardiology center
37 45.6
Underwent Exercise ECG 22 27
Underwent Coronary angiogram 10 12.3
Underwent Revascularization 7 7.3
Re-admitted with Coronary events 6 7.4
ECG, electrocardiogram.No significant association was found between death at
1 year and history of smoking, hypertension, dyslipidae-
mia, time taken for presentation, door to needle time,
ejection fraction and hypotension during the index ad-
mission and the mode of admission to hospital.
Discussion
STEMI was diagnosed with reasonable accuracy in our
study by clinical and ECG criteria. Troponin levels were
obtained in a minority of patients because of the un-
availability of the test in the state sector and the high
cost in private-sector laboratories.
Despite coronary vascular disease being the largest cause
of mortality among Sri Lankan adults, no study has de-
scribed the presentation, management, and outcomes of
STEMI; likely because of lack of resources and funding.
Peradeniya Teaching Hospital is one of the two largest
tertiary-care institutions in the area, and many smaller
hospitals redirect patients with ACS to this unit; the sam-
ple can thus be considered representative. Percutaneous
Coronary Interventions (PCI) or CABG is not performed
at this hospital and specialized cardiology services are
available only at the Teaching Hospital Kandy situated
4 km away. At the time of the study Primary PCI was not
routinely performed at this instituttion either.
The prevalences of smoking (58%) and diabetes (30.8%)
in this study are comparable with data from regional and
global studies [5,9]. The prevalences of hypertension, dys-
lipidemia, and preexisting coronary heart disease (Table 1)
were considerably lower than in other studies. Mohanan
et al. reported the prevalence of hypertension and previ-
ous IHD among patients in Kerala, India, presenting with
ACS to be 48% and 14% [9]; the Access study investigators
reported higher prevalences of 65% and 26%, respectively
[5]. The prevalences of hypertension and diabetes among
adult Sri Lankans are 23% and 10.8%, respectively [10,11],
but they seem to be underreported in the current study.
In Sri Lanka, the first recognition of risk factors for car-
diovascular disease is often at presentation for STEMI and
may explain the low prevalence of risk factors reported in
the current study.
Late presentation; contraindications; and other factors
that are undocumented and therefore unknown rendered
27% of patients ineligible for thrombolysis following
STEMI. Better training of staff can facilitate recognition
of the need for thrombolysis at presentation. Better rec-
ord keeping is also essential.
Delayed presentation resulting in ineligibility for thromb-
olysis was mainly pre-hospital, and similar delays have
been observed in other studies carried out in Sri Lanka.
Constantine et al. reported median pre-hospital delays of
130 min in 1997 and 720 min in 1999, and the delay was
longer in patients who sought pre-hospitalization medical
advice than in those who presented directly [12,13]. In our
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tients presenting directly to our center and 75 min (mean
281 min) in those presenting through another hospital or
general practitioner, a trend similar to those reported pre-
viously [13]. However it did not reach statistical signifi-
cance. The longer mean than median time to presentation
is the result of several patients presenting more than
12 hours following onset of pain. Mohanan et al. recently
reported time from ACS symptom onset to ER presenta-
tion of over 6 hours in India [9].
While time to presentation has greatly improved, there
is still considerable delay at peripheral hospitals and clinics,
and while we did not identify an association between time
to presentation and 1-year mortality, this could have been
because of our relatively small sample size.
In the present study, 83% of eligible patients under-
went thrombolysis, a result consistent with that of
Rajapakse et al., who reported that thrombolysis was
performed in 84.6% of a cohort of AMI patients at an-
other tertiary-care institution in Sri Lanka, the National
Hospital Colombo, in 2008 [8]. Both figures show a tre-
mendous improvement from the 17% reported in 1999
[13]. However a large proportion of patients with STEMI
(27%) did not receive thrombolysis or PCI in our study.
Access investigators who studied the outcomes of ACS
patients in the developing countries of Latin America,
the Middle East, and Africa reported that 39% of STEMI
patients did not receive thrombolysis or PCI [5]. However,
in this multi-national survey, which included 11,731 pa-
tients, the overall rates for angiography and PCI were 58
and 35%, respectively.
Our data suggest that time delay to presentation to a
tertiary-care center is a critical factor that reduced pa-
tients’ eligibility for thrombolysis. Reasons for this delay
are likely 1) the absence of organized emergency medical
transport [9] and cardiac response teams, requiring pa-
tients to provide their own transportation to the hos-
pital; and 2) lack of patient awareness regarding ACS.
The benefits of early thrombolytic therapy are well
established. Mean absolute reduction in mortality per
hour of delay is 1.6 (standard deviation, 0.6) per 1,000
patients [12]. Median door-to-needle time in our study
was 64 min; the mean of 96 min was due to late thromb-
olysis in some patients because of difficulty making a
definitive diagnosis of STEMI. Guidelines recommend a
door-to-needle time of less than 30 min. This was
achieved in only 16.9% of our patients, but thrombolysis
was performed within 60 min of admission in 47% and
within 90 min of admission in 66%. In a previous study,
a median door-to-needle time of 70 min was reported
[12]. In Malaysia the median door-to-needle time was
48–54 min in a prospective study in which medical and
emergency department doctors administered thromboly-
sis [14]. Mohanan et al. reported that less than one-thirdof patients undergoing thrombolysis had door-to-needle
times of more than 30 min in India [9]. Door-to-needle
time is a critical factor in the management of STEMI
and first-contact doctors at all hospitals should be edu-
cated in early diagnosis and immediate thrombolysis.
More than 95% of STEMI patients received aspirin,
clopidogrel, and a statin on presentation to our unit.
However, a considerable proportion (84%) of STEMI pa-
tients who presented initially to another hospital or a
general practitioner did not receive aspirin prior to being
referred for thrombolysis. In 2010, Rajapakse et al. re-
ported that aspirin and clopidogrel loading was performed
in only 69% and 61% of patients, respectively [8]. Our use
of aspirin and clopidogrel on admission seems to be satis-
factory and compares well with other studies of the region
[9] and of the developing world in general [5]. Continued
therapy with aspirin, clopidogrel, and statin medication
was observed in more than 88% of participants during
hospitalization and on discharge. Aspirin was the medica-
tion most likely to be withheld, mostly for reasons of
epigastric pain or presumed gastrointestinal hemorrhage.
An ACEI or ARB was administered to over 90% of pa-
tients during hospitalization and to over 88% on discharge.
At the end of 1 year, the use of the above medications
remained over 82%. Access investigators who studied over
11,000 patients with ACS in the developing world re-
ported the use of ACEIs to be 68% [5]. The World Health
Organization considers the use of aspirin, statin and blood
pressure-lowering agents post discharge in ACS patients
to be cost-effective strategies and are considered best buys
[15]. Nitrates were prescribed to more than 59% of pa-
tients during hospitalization and on discharge.
Intravenous beta blockers were not used in the acute
management of STEMI in the present study or in previous
Sri Lankan studies. However 35% of patients received oral
beta blockers during the initial assessment. Intravenous
beta blockers followed by oral beta blockers should be ad-
ministered immediately, in the absence of contraindica-
tions, to all patients with STEMI [16]. Underutilization of
intravenous beta blockers persists and should be analyzed
in future studies. Oral beta blockers were prescribed at
discharge to 34% of our study patients, compared with
78% in other developing countries [5].
Eighteen (22%) of our patients had complications during
the post-infarction period, the majority of which were
from cardiac causes. Only one patient developed a major
gastrointestinal hemorrhage following thrombolytic ther-
apy. Seventy six (85%) of our patients had pre-discharge
echocardiography performed and 14% had evidence of
left ventricular dysfunction, defined as an ejection frac-
tion <40%, at the time of discharge. Rajapakse et al. also
reported a complication rate of 25% in their ACS pa-
tients [8]. Both studies show an improvement from the
previously reported incidence of 37% [13] that may be
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of thrombolysis. There were no in-hospital deaths dur-
ing the index admission in the present study, which
probably reflects our small sample size. Mohanan et al.
reported an in-hospital mortality of 4.3–8.6% among
various cardiac registries globally [9].
This study examined 1-year survival of post-STEMI
patients in Sri Lanka. Ten of the initial 81 STEMI pa-
tients were deceased at 1-year follow-up. The 1-year
mortality of 12.3% in our study was slightly greater than
the observed value of 8–10% in the major thrombolysis
trials [17]. Similarly, an all-cause death rate of 7.3% at
1 year was observed by the Access investigators [5]. The
higher 1-year mortality observed in the present study is
probably the result of late presentation at the index
admission, underutilization of thrombolysis, a longer-
than-recommended door-to-needle time, and a very low
rate of coronary intervention in the post-infarction
period. However, there were no significant associations
of mortality at 1 year with either time to presentation or
the door-to-needle time, probably because of our small
study sample.
Meta-analysis has shown primary PCI to be superior
to thrombolysis in the treatment of STEMI and to benefit
long term survival and reduce strokes, recurrent ischemia,
and reinfarction [18]. Unfortunately, only a minority of Sri
Lankan patients have the opportunity to undergo primary
PCI at present. Only 27% of patients from the current
study went onto have a cardiac stress test, only 12.3%
underwent coronary angiography, and only 7.3% under-
went revascularization within 1 year of STEMI. Regionally,
in India 7.5–12% of patients presenting with ACS undergo
primary PCI and 20% undergo angiography [9,19]. By
comparison, western countries report rates of 56.3% for
angiography, 40.4% for percutaneous intervention, and
3.4% for coronary artery bypass grafting for patients pre-
senting with acute STEMI [20,21]. Cardiac care infrastruc-
ture, personnel, and protocols in Sri Lanka need to keep
pace with expanding facilities globally to confer the bene-
fits of new developments to patients.
Limitations
Limitations of this study were its relatively small sample
size, that it was a single-center investigation, and that it
included only patients in the acute-care setting, which
may have led to underestimation of the event rates, since
patients who were dead on admission would not have
been included in our analysis. Absence of the causes of
death for those who died during the first year after
STEMI is another notable limitation.
Conclusions
Sri Lanka still relies heavily on thrombolysis for the
acute management of STEMI. Pre-hospital delays remaina critical factor in underutilization of thrombolysis, and
recommended door-to-needle time is achieved in only a
minority. Primary PCI and use of coronary intervention
in the post-infarction period remain underutilized. In an
environment that still relies heavily on thrombolysis as
the primary treatment option for STEMI, more stream-
lined services, strict adherence to guidelines, and train-
ing of first-contact physicians is paramount in reducing
mortality from myocardial infarction.
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